These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 38272563)
1. Multimodal profiling of chordoma immunity reveals distinct immune contextures. van Oost S; Meijer DM; Ijsselsteijn ME; Roelands JP; van den Akker BEMW; van der Breggen R; Briaire-de Bruijn IH; van der Ploeg M; Wijers-Koster PM; Polak SB; Peul WC; van der Wal RJP; de Miranda NFCC; Bovee JVMG J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38272563 [TBL] [Abstract][Full Text] [Related]
2. Complex immune microenvironment of chordoma: a road map for future treatment. Niu HQ; Zheng BY; Zou MX; Zheng BW J Immunother Cancer; 2024 Jun; 12(6):. PubMed ID: 38908855 [TBL] [Abstract][Full Text] [Related]
3. Defective HLA Class I Expression and Patterns of Lymphocyte Infiltration in Chordoma Tumors. Patel SS; Nota SP; Sabbatino F; Nielsen GP; Deshpande V; Wang X; Ferrone S; Schwab JH Clin Orthop Relat Res; 2021 Jun; 479(6):1373-1382. PubMed ID: 33273248 [TBL] [Abstract][Full Text] [Related]
4. Unravelling the role of immune cells and FN1 in the recurrence and therapeutic process of skull base chordoma. Huo X; Ma S; Wang C; Song L; Yao B; Zhu S; Li P; Wang L; Wu Z; Wang K Clin Transl Med; 2023 Oct; 13(10):e1429. PubMed ID: 37784253 [TBL] [Abstract][Full Text] [Related]
5. DNA methylation, combined with RNA sequencing, provide novel insight into molecular classification of chordomas and their microenvironment. Baluszek S; Kober P; Rusetska N; Wągrodzki M; Mandat T; Kunicki J; Bujko M Acta Neuropathol Commun; 2023 Jul; 11(1):113. PubMed ID: 37434245 [TBL] [Abstract][Full Text] [Related]
6. Single-cell transcriptome profiling reveals intra-tumoral heterogeneity in human chordomas. Duan W; Zhang B; Li X; Chen W; Jia S; Xin Z; Jian Q; Jian F; Chou D; Chen Z Cancer Immunol Immunother; 2022 Sep; 71(9):2185-2195. PubMed ID: 35084549 [TBL] [Abstract][Full Text] [Related]
8. Unraveling molecular advancements in chordoma tumorigenesis and treatment response: a review of scientific discoveries and clinical implications. Jin MC; Connolly ID; Ravi K; Tobert DG; MacDonald SM; Shin JH Neurosurg Focus; 2024 May; 56(5):E18. PubMed ID: 38691860 [TBL] [Abstract][Full Text] [Related]
9. Expression of ezrin, MMP-9, and COX-2 in 50 chordoma specimens: a clinical and immunohistochemical analysis. Froehlich EV; Scheipl S; Lazàry A; Varga PP; Schmid C; Stammberger H; Beham A; Bodo K; Schroettner H; Quehenberger F; Windhager R; Liegl B; Leithner A Spine (Phila Pa 1976); 2012 Jun; 37(13):E757-67. PubMed ID: 22228328 [TBL] [Abstract][Full Text] [Related]
10. Multi-spectral immunofluorescence evaluation of the myeloid, T cell, and natural killer cell tumor immune microenvironment in chordoma may guide immunotherapeutic strategies. Lopez DC; Robbins YL; Kowalczyk JT; Lassoued W; Gulley JL; Miettinen MM; Gallia GL; Allen CT; Hodge JW; London NR Front Oncol; 2022; 12():1012058. PubMed ID: 36338744 [TBL] [Abstract][Full Text] [Related]
11. Differences in TCR repertoire and T cell activation underlie the divergent outcomes of antitumor immune responses in tumor-eradicating versus tumor-progressing hosts. Woolaver RA; Wang X; Krinsky AL; Waschke BC; Chen SMY; Popolizio V; Nicklawsky AG; Gao D; Chen Z; Jimeno A; Wang XJ; Wang JH J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33414263 [TBL] [Abstract][Full Text] [Related]
12. T gene isoform expression pattern is significantly different between chordomas and notochords. Wang K; Hu Q; Wang L; Chen W; Tian K; Cao C; Wu Z; Jia G; Zhang L; Zeng C; Zhang J Biochem Biophys Res Commun; 2015 Nov; 467(2):261-7. PubMed ID: 26435504 [TBL] [Abstract][Full Text] [Related]
13. HOXA7, HOXA9, and HOXA10 are differentially expressed in clival and sacral chordomas. Jäger D; Barth TFE; Brüderlein S; Scheuerle A; Rinner B; von Witzleben A; Lechel A; Meyer P; Mayer-Steinacker R; Baer AV; Schultheiss M; Wirtz CR; Möller P; Mellert K Sci Rep; 2017 May; 7(1):2032. PubMed ID: 28515451 [TBL] [Abstract][Full Text] [Related]
14. MicroRNA expression profiling reveals the potential function of microRNA-31 in chordomas. Bayrak OF; Gulluoglu S; Aydemir E; Ture U; Acar H; Atalay B; Demir Z; Sevli S; Creighton CJ; Ittmann M; Sahin F; Ozen M J Neurooncol; 2013 Nov; 115(2):143-51. PubMed ID: 23912551 [TBL] [Abstract][Full Text] [Related]
15. PD-1, PD-L1, PD-L2 expression in the chordoma microenvironment. Mathios D; Ruzevick J; Jackson CM; Xu H; Shah SR; Taube JM; Burger PC; McCarthy EF; Quinones-Hinojosa A; Pardoll DM; Lim M J Neurooncol; 2015 Jan; 121(2):251-9. PubMed ID: 25349132 [TBL] [Abstract][Full Text] [Related]
16. Role of immunotherapy in treatment refractory chordomas: review of current evidence. Alexander AY; Dhawan S; Venteicher AS Front Surg; 2024; 11():1375567. PubMed ID: 38881706 [TBL] [Abstract][Full Text] [Related]